Sectors
PRLD
Prelude Therapeutics Incorporated
5.60
2 x 4.02
2 x 6.70
bid
ask
+
0.13
2.38%
2 @ 04:45 PM
5.67 +0.07 (1.25%)
| Ytd | 93.10% | |
| 1y | 362.81% |
5.24
day range
5.63
0.98
52 week range
6.83
| Open | 5.39 | Prev Close | 5.47 | Low | 5.24 | High | 5.63 | Mkt Cap | 446.01M |
| Vol | 737.63K | Avg Vol | 476.43K | EPS | -0.73 | P/E | N/A | Forward P/E | -0.82 |
| Beta | 1.55 | Short Ratio | 7.51 | Inst. Own | 84.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 4.93 | 200-d Avg | 3.52 | 1yr Est | 5.00 |
| Income Statement | |||
| Total Revenue | 5.70M | ||
| Revenues (USD) | 5.70M | ||
| Gross Profit | 5.70M | ||
| Operating Expenses | 21.16M | ||
| Research and Development Expense | 16.13M | ||
| Selling, General and Administrative Expense | 5.03M | ||
| Operating Income | -15.45M | ||
| Net Income | -13.92M | ||
| Net Income Common Stock | -13.92M | ||
| Net Income Common Stock (USD) | -13.92M | ||
| Consolidated Income | -13.92M | ||
| Earnings per Basic Share | -0.14 | ||
| Earnings per Basic Share (USD) | -0.14 | ||
| Earnings per Diluted Share | -0.14 | ||
| Earning Before Interest & Taxes (EBIT) | -13.92M | ||
| Earning Before Interest & Taxes (USD) | -13.92M | ||
| Weighted Average Shares | 98.39M | ||
| Weighted Average Shares Diluted | 98.39M | ||
| Balance Sheet | |||
| Cash and Equivalents | 29.73M | ||
| Cash and Equivalents (USD) | 29.73M | ||
| Investments | 125.43M | ||
| Investments Current | 125.43M | ||
| Current Assets | 154.90M | ||
| Property, Plant & Equipment Net | 30.79M | ||
| Total Assets | 189.36M | ||
| Debt Current | 2.78M | ||
| Total Debt | 17.65M | ||
| Current Liabilities | 38.04M | ||
| Debt Non-Current | 14.87M | ||
| Total Liabilities | 55.63M | ||
| Accumulated Retained Earnings (Deficit) | -707.37M | ||
| Accumulated Other Comprehensive Income | -227.00K | ||
| Shareholders Equity | 133.73M | ||
| Shareholders Equity (USD) | 133.73M | ||
| Assets Non-Current | 34.47M | ||
| Total Debt (USD) | 17.65M | ||
| Deferred Revenue | 25.25M | ||
| Liabilities Non-Current | 17.59M | ||
| Trade and Non-Trade Payables | 2.03M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 743.00K | ||
| Net Cash Flow from Financing | 85.82M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 4.74M | ||
| Issuance (Purchase) of Equity Shares | 90.20M | ||
| Net Cash Flow from Investing | -65.50M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -65.50M | ||
| Net Cash Flow from Operations | -15.57M | ||
| Share Based Compensation | 2.03M | ||